OncoGenex To Present At The BioContact Quebec 2008 Annual Conference



    BOTHELL, WA and VANCOUVER, Oct. 1 /CNW/ - OncoGenex Pharmaceuticals, Inc
(NASDAQ:   OGXI) will present at the BioContact Quebec 2008 annual partnering
symposium on October 2 at 4:30 pm ET in the Salle Laval at the Chateau
Frontenac in Quebec City. OncoGenex' President and Chief Executive Officer,
Scott Cormack, will provide a corporate overview at the conference, including
a discussion of the Company's lead cancer drug candidate OGX-011 nearing
completion of multiple Phase 2 clinical trials.

    About OncoGenex Pharmaceuticals

    OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the
development and commercialization of new cancer therapies that address unmet
needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with
each product candidate having a distinct mechanism of action and representing
a unique opportunity for cancer drug development. OGX-011, the lead candidate
currently completing five Phase 2 clinical studies in prostate, lung and
breast cancers, is designed to inhibit the production of a specific protein
associated with treatment resistance; OGX-427 and SN2310 are in Phase 1
clinical development; and CSP-9222 and OGX-225 are currently in pre-clinical
development. More information is available at www.oncogenex.com.





For further information:

For further information: OncoGenex Media and Investor Contact: Jason I.
Spark, Porter Novelli Life Sciences, (619) 849-6005,
jspark@pnlifesciences.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890